for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Chimerix Inc

CMRX.OQ

Latest Trade

2.42USD

Change

-0.03(-1.02%)

Volume

35,239

Today's Range

2.38

 - 

2.43

52 Week Range

1.75

 - 

4.39

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.44
Open
2.43
Volume
35,239
3M AVG Volume
7.74
Today's High
2.43
Today's Low
2.38
52 Week High
4.39
52 Week Low
1.75
Shares Out (MIL)
61.27
Market Cap (MIL)
149.50
Forward P/E
-2.23
Dividend (Yield %)
--

Next Event

Chimerix Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Chimerix Reports Q2 Loss Per Share $0.35

Chimerix Announces Exclusive Worldwide License Of CX-01 For Acute Myeloid Leukemia

Chimerix Reports Q1 Loss Per Share Of $0.35

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Chimerix Inc

Chimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses. It is also advancing the development of CMX521 for the treatment and prevention of norovirus. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against all five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. Oral and IV formulations of brincidofovir are in development, both of which deliver the active antiviral directly to the site of viral replication.

Industry

Biotechnology & Drugs

Contact Info

2505 Meridian Pkwy Ste 100

+1.919.8061074

http://www.chimerix.com/

Executive Leadership

Martha J. Demski

Chairman of the Board

Michael A. Sherman

Chief Executive Officer

Michael T. Andriole

Chief Financial Officer, Chief Business Officer

Michael A. Alrutz

Senior Vice President, General Counsel

Roy W. Ware

Chief Manufacturing and Technology Officer

Key Stats

2.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.650

2017

-1.510

2018

-1.430

2019(E)

-1.094
Price To Earnings (TTM)
--
Price To Sales (TTM)
16.56
Price To Book (MRQ)
0.84
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-38.90
Return on Equity (TTM)
-36.43

Latest News

BRIEF-Chimerix Announces Martha J. Demski As Board Chair

* CHIMERIX ANNOUNCES MARTHA J. DEMSKI AS BOARD CHAIR; APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS

BRIEF-Chimerix Announces Q4 Loss Per Share $0.41

* CHIMERIX ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Arrowmark Colorado Holdings Llc Reports 5.7 PCT Passive Stake In Chimerix As Of Dec 31, 2017

* ARROWMARK COLORADO HOLDINGS LLC REPORTS 5.7 PERCENT PASSIVE STAKE IN CHIMERIX INC AS OF DECEMBER 31, 2017 - SEC FILING Source text - (http://bit.ly/2EeZ3kp) Further company coverage:

BRIEF-Chimerix Initiates Adapt Study For Oral Brincidofovir

* CHIMERIX INITIATES ADAPT STUDY FOR ORAL BRINCIDOFOVIR AND ADVANCES IV BRINCIDOFOVIR TO PATIENT STUDIES Source text for Eikon: Further company coverage:

BRIEF-Chimerix reports Q3 loss of $0.37/shr

* Q3 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Chimerix Inc files for mixed shelf of up to $250 million

* Files for mixed shelf of up to $250 million - SEC filing Source text : (http://bit.ly/2m8BtgL) Further company coverage:

BRIEF-Chimerix Inc entered into agreement with Cowen and Co

* On November 8, 2017, co entered into an at market issuance, or ATM, sales agreement with Cowen and Company LLC - SEC filing

BRIEF-Chimerix Inc appoints Heather Knight-Trent vice president of regulatory affairs

* Chimerix appoints Heather Knight-Trent, PHARMD, as vice president of regulatory affairs Source text for Eikon: Further company coverage:

BRIEF-Chimerix reports Q2 loss per share $0.36

* Q2 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Chimerix Q1 loss per share $0.38

* Q1 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Chimerix Q4 loss per share $0.32

* Chimerix announces fourth quarter and full year 2016 financial results

BRIEF-Chimerix Q3 loss per share $0.37

* Chimerix inc- brincidofovir iv single and multiple dose data expected to report out in 2017

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up